IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPY

David S Alberts, H. S. George Chen, Barbara Soehnlen, Sydney E. Salmon, Earl A. Surwit, Laurie Young, Thomas E. Moon

Research output: Contribution to journalArticle

131 Citations (Scopus)

Abstract

95 clinical trials of anticancer drugs were done in 40 patients with advanced ovarian cancer who had undergone an in-vitro soft-agar human tumour stem-cell assay for drug sensitivity. In the 95 clinical trials, 13 of 21 patients responded clinically to drugs predicted to be effective in vitro, while in 73 of 74 instances in which drug resistance had been predicted in vitro there was no response to treatment. 2 patients achieved a complete remission of 1 and 12+ months and 11 had partial remissions lasting a median of four months. Prediction of in-vitro resistance was 99% accurate. The 62% complete or partial remission rate to agents with proven in-vitro efficacy was achieved in extensively pretreated ovarian cancer patients who were unlikely to respond to empirically chosen secondary agents. The human tumour stem-cell assay, in which ovarian tumour colony-forming units are grown in a two-layer agar-culture system incorporating tests for drug sensitivity or resistance, can be effectively used to plan a suitable chemotherapy regimen for ovarian cancer patients.

Original languageEnglish (US)
Pages (from-to)340-342
Number of pages3
JournalThe Lancet
Volume316
Issue number8190
DOIs
StatePublished - 1980

Fingerprint

Ovarian Neoplasms
Tumor Stem Cell Assay
Drug Therapy
Pharmaceutical Preparations
Agar
Clinical Trials
Drug Resistance
Stem Cells
In Vitro Techniques
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Alberts, D. S., George Chen, H. S., Soehnlen, B., Salmon, S. E., Surwit, E. A., Young, L., & Moon, T. E. (1980). IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPY. The Lancet, 316(8190), 340-342. https://doi.org/10.1016/S0140-6736(80)90340-2

IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPY. / Alberts, David S; George Chen, H. S.; Soehnlen, Barbara; Salmon, Sydney E.; Surwit, Earl A.; Young, Laurie; Moon, Thomas E.

In: The Lancet, Vol. 316, No. 8190, 1980, p. 340-342.

Research output: Contribution to journalArticle

Alberts, DS, George Chen, HS, Soehnlen, B, Salmon, SE, Surwit, EA, Young, L & Moon, TE 1980, 'IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPY', The Lancet, vol. 316, no. 8190, pp. 340-342. https://doi.org/10.1016/S0140-6736(80)90340-2
Alberts, David S ; George Chen, H. S. ; Soehnlen, Barbara ; Salmon, Sydney E. ; Surwit, Earl A. ; Young, Laurie ; Moon, Thomas E. / IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPY. In: The Lancet. 1980 ; Vol. 316, No. 8190. pp. 340-342.
@article{22e2b17339404403918da2a0db5f9155,
title = "IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPY",
abstract = "95 clinical trials of anticancer drugs were done in 40 patients with advanced ovarian cancer who had undergone an in-vitro soft-agar human tumour stem-cell assay for drug sensitivity. In the 95 clinical trials, 13 of 21 patients responded clinically to drugs predicted to be effective in vitro, while in 73 of 74 instances in which drug resistance had been predicted in vitro there was no response to treatment. 2 patients achieved a complete remission of 1 and 12+ months and 11 had partial remissions lasting a median of four months. Prediction of in-vitro resistance was 99{\%} accurate. The 62{\%} complete or partial remission rate to agents with proven in-vitro efficacy was achieved in extensively pretreated ovarian cancer patients who were unlikely to respond to empirically chosen secondary agents. The human tumour stem-cell assay, in which ovarian tumour colony-forming units are grown in a two-layer agar-culture system incorporating tests for drug sensitivity or resistance, can be effectively used to plan a suitable chemotherapy regimen for ovarian cancer patients.",
author = "Alberts, {David S} and {George Chen}, {H. S.} and Barbara Soehnlen and Salmon, {Sydney E.} and Surwit, {Earl A.} and Laurie Young and Moon, {Thomas E.}",
year = "1980",
doi = "10.1016/S0140-6736(80)90340-2",
language = "English (US)",
volume = "316",
pages = "340--342",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "8190",

}

TY - JOUR

T1 - IN-VITRO CLONOGENIC ASSAY FOR PREDICTING RESPONSE OF OVARIAN CANCER TO CHEMOTHERAPY

AU - Alberts, David S

AU - George Chen, H. S.

AU - Soehnlen, Barbara

AU - Salmon, Sydney E.

AU - Surwit, Earl A.

AU - Young, Laurie

AU - Moon, Thomas E.

PY - 1980

Y1 - 1980

N2 - 95 clinical trials of anticancer drugs were done in 40 patients with advanced ovarian cancer who had undergone an in-vitro soft-agar human tumour stem-cell assay for drug sensitivity. In the 95 clinical trials, 13 of 21 patients responded clinically to drugs predicted to be effective in vitro, while in 73 of 74 instances in which drug resistance had been predicted in vitro there was no response to treatment. 2 patients achieved a complete remission of 1 and 12+ months and 11 had partial remissions lasting a median of four months. Prediction of in-vitro resistance was 99% accurate. The 62% complete or partial remission rate to agents with proven in-vitro efficacy was achieved in extensively pretreated ovarian cancer patients who were unlikely to respond to empirically chosen secondary agents. The human tumour stem-cell assay, in which ovarian tumour colony-forming units are grown in a two-layer agar-culture system incorporating tests for drug sensitivity or resistance, can be effectively used to plan a suitable chemotherapy regimen for ovarian cancer patients.

AB - 95 clinical trials of anticancer drugs were done in 40 patients with advanced ovarian cancer who had undergone an in-vitro soft-agar human tumour stem-cell assay for drug sensitivity. In the 95 clinical trials, 13 of 21 patients responded clinically to drugs predicted to be effective in vitro, while in 73 of 74 instances in which drug resistance had been predicted in vitro there was no response to treatment. 2 patients achieved a complete remission of 1 and 12+ months and 11 had partial remissions lasting a median of four months. Prediction of in-vitro resistance was 99% accurate. The 62% complete or partial remission rate to agents with proven in-vitro efficacy was achieved in extensively pretreated ovarian cancer patients who were unlikely to respond to empirically chosen secondary agents. The human tumour stem-cell assay, in which ovarian tumour colony-forming units are grown in a two-layer agar-culture system incorporating tests for drug sensitivity or resistance, can be effectively used to plan a suitable chemotherapy regimen for ovarian cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=0018827656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018827656&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(80)90340-2

DO - 10.1016/S0140-6736(80)90340-2

M3 - Article

C2 - 6105478

AN - SCOPUS:0018827656

VL - 316

SP - 340

EP - 342

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 8190

ER -